Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq analysis of the transcriptomic profiles of ATO+DAC-treated THP-1 cell lines expressing p53-R282W, vector control, or p53-R282W with IRF7 knockdown

ABSTRACT: To investigate the transcriptomic effects of ATO and DAC co-treatment in THP-1 cells expressing different p53 contexts, RNA-seq analysis was conducted on cell lines expressing p53-R282W, vector control, or p53-R282W with IRF7 knockdown. Cells were treated with arsenic trioxide (1 μg/mL) and decitabine (5 μM) prior to total RNA extraction. Purified mRNA was subjected to high-throughput sequencing using the Illumina HiSeq platform. Sequencing reads that passed quality control were trimmed using Cutadapt and used for downstream transcriptomic analysis.

ORGANISM(S): Homo sapiens

PROVIDER: GSE269126 | GEO | 2024/07/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNAseq analysis for transcriptomes of ATO treated U937 cell lines expressing p53-R280I or p53 wild-type

Project description:To globally evaluate to what extend the p53 mutant transcription activity can be restored by arsenic trioxide (ATO), p53-null U937 cells introduced with p53-R280I or wild-type p53 were treated with or without 1 μg/mL ATO. mRNA was isolated and then subject to deep sequencing, using Illumina HiSeq. The sequence reads that passed quality filters were analyzed using Cutadapt.

2024-08-01 | GSE213678 | GEO

RNAseq analysis for transcriptomes of ATO treated U937 cell lines expressing 10 type 1 p53 mutants, type-3 p53-R273H, p53 null, or p53 wild-type

Project description:To globally evaluate to what extend type-1 p53 mutant transcription activity can be restored by arsenic trioxide (ATO) (compared to wild-type p53), p53-null U937 cells introduced with 10 frequent type-1 p53, type-3 p53-R273H (negative control), empty vector or wild-type p53 were treated with or without 1 μg/mL ATO. mRNA was isolated and then subject to deep sequencing, using Illumina HiSeq. The sequence reads that passed quality filters were analyzed using Cutadapt. Results and conclusions: The type-1 p53 mutants are the major cellular targets of ATO in the current cell contexts. The expression profiles of well-established p53 targets in cells expressing wild-type p53 highly correlated with the ones in cells expressing ATO-rescued type-1 mutants, but not those in cells expressing ATO-treated R273H. In cells harboring type-1 mutants, the median expression levels of these targets were elevated by ATO to extents comparable to wild-type p53.

2024-08-01 | GSE182565 | GEO

Transcriptome analysis of mutant p53 (p53-V272M, p53-R282W) rescued by arsenic trioxide (ATO)

Project description:Transcriptome analysis of mutant p53 (p53-V272M, p53-R282W) rescued by arsenic trioxide (ATO)

| PRJNA636976 | ENA

Transcriptome analysis of mutant p53 (p53-V272M, p53-R282W) rescued by arsenic trioxide (ATO)

Project description:The goals of this study are to compare transcriptome of mutant p53 rescued by arsenic trioxide

2023-06-03 | GSE151696 | GEO

Identification of arsenic trioxide (ATO)-rescuable p53 mutations and temperature-sensitive p53 mutations in p53-null U937 cells using a patient-derived 800 p53 mutation library

Project description:Thousands of diverse p53 mutations have been identified in cancer. The leukemia-treating drug arsenic trioxide (ATO) rescues a part of p53 mutations with high potency. To repurpose ATO in personalized p53-targeted therapy, here we quantitatively determined the frequent 800 p53 mutations, covering 95.8% p53 missense-mutation cases in cancer, for their rescue potencies of cell growth inhibitory activity and mouse tumor suppressive activity by ATO. Furthermore, we determined the temperature sensitivity of 800 mutations in mammalian U937 cells and founded that ATO preferentially rescued temperature-sensitive subtype of structural p53 mutants.

2024-08-01 | GSE182927 | GEO

Single-Cell RNA-Sequencing facilitates the effectiveness analysis of ATO and DAC co-treatment in PBMCs from PANDA-T0 trial

Project description:The goals of this study is to reveal the transcriptome of structural p53 mutations rescued by ATO and DAC in AML/MDS patients.

2024-07-31 | GSE269125 | GEO

RNA-seq analysis of the transcriptomic profiles of ATO+DAC-treated THP-1 cell lines expressing p53-R282W, vector control, or p53-R282W with IRF7 knockdown

Project description:RNA-seq analysis of the transcriptomic profiles of ATO+DAC-treated THP-1 cell lines expressing p53-R282W, vector control, or p53-R282W with IRF7 knockdown

| PRJNA1120356 | ENA

RNAseq analysis for transcriptomes of DAC treated myeloid malignant cell lines expressing p53-R282W

Project description:To globally evaluate transcriptome treated by decitabine (DAC) in THP-1 and U937 cells expressing p53-R282W, cells were treated with DMSO or DAC. mRNA was isolated and then subject to deep sequencing, using Illumina HiSeq Xten. The sequence reads that passed quality filters were analyzed using htseq. The expressions had been validated using qRT–PCR using SYBR Green assays. Results and conclusions: Global transcriptional change of THP-1 expressing p53-R282W treated with 5 μM DAC was analyzed. Protein interaction network and Enrichment assay was analyzed with the 216 upregulated genes exemplified by ISG15 and IFI27) (Gfold ≥0.4, (RPKM+1 fold change > 1.5), the type I interferon signaling was hit .Similar observations were achieved in U937 cells.

2025-01-10 | GSE125968 | GEO

Gene expression data of cancer cells overexpressing p53-R282W with or without decitabine (DAC) treatment

Project description:The goals of this study are to compare transcriptome of tumor cells with p53-R282W treated by DAC

2024-04-30 | GSE173643 | GEO

Transcriptome analysis of mutant p53 rescued by arsenic trioxide (ATO)

Project description:Transcriptome analysis of mutant p53 rescued by arsenic trioxide (ATO)

| PRJNA595114 | ENA